• Multimodal first-in-class cancer therapeutics against intractable targets.

Opening the
Therapeutic Window for Cancer Immunotherapy

The generation of solid tumor targeting domains specific to cancer cells remains a significant challenge in the biopharmaceutical industry. GO Therapeutics’ targeting platforms and technologies hold the promise to unlock the full potential of antibody-drug conjugates, bi-specific T-cell engagers, and immune-based cell therapies.

GO Therapeutics is developing a range of cancer drug candidates that are exquisitely tumor specific.

We are developing antibodies against a novel class of tumor-specific glycoprotein antigens. These antigens are not found on healthy cells, making them ideal targets for bi-specific antibody T-cell engagement, CAR-T and ADC therapies. GO’s lead antibody development program is based on a bispecific antibody for T cell-redirection therapy.
Background
TARGETED IMMUNOTHERAPY - GOT

TARGETED IMMUNOTHERAPY

Addressing novel targets
with different biology.
ADVANCED TOOLS AND TECHNIQUES GOT

ADVANCED TOOLS AND
TECHNIQUES

Unlocking the potential of ADCs, T-cell
bi-specifics, and immune-based cell therapies.
WHAT'S IN THE PIPELINE GOT

WHAT'S IN THE PIPELINE

Multimodal cancer therapeutics
against intractable targets.
Background

Our Mission

GO Therapeutic’s mission is to apply the latest advances in glycobiology to create cancer drugs that are highly potent and less toxic. Our antibodies against tumor-specific antigens can be used in a multimodal approach to killing cancer. GO’s products aim to provide transformative treatment benefits to patients with cancer.

THE LEADER IN CANCER GLYCOPROTEOMICS

GO Therapeutics’ team features leading authorities in the science O-glycosylation, or the cancer glycoproteome. Our deep mechanistic understanding of O-glycosylation, know-how and proprietary tools enables us to create cancer therapeutics that are highly specific and potent.
Background

Our Science

Glycans are involved in fundamental molecular and cell biology processes occurring in cancer, such as cell signalling and communication, tumor cell dissociation and invasion, cell–matrix interactions, tumor angiogenesis, immune modulation and metastasis formation.
The roles of glycans in cancer have been highlighted by the fact that altered glycosylation regulate the development and progression of cancer, serving as important biomarkers and providing a set of specific targets for therapeutic intervention.
Background

Leadership

CONSTANTINE THEODOROPULOS

CEO and Co-Founder

THAYER WHITE
Ph.D.

CSO and Co-Founder

HANS WANDALL
MD. Ph.D.

Senior Scientific Consultant

HENRIK CLAUSEN
D.Sc.

Senior Scientific Consultant
Latest News 2

Latest News

GO Therapeutics appoints Dr. Robert J. Wills to Board of Directors

GO Therapeutics, a company exploiting new advances in glycoproteomics to develop novel, multimodal first-in-class cancer therapeutics against intractable targets, today announced the appointment of Robert J. Wills, Ph.D. to the Company’s Board of Directors.
Dr. Wills is an accomplished, seasoned senior executive whose 37-year career spans directing R&D, business . . . . .